Found 404 results
Porichis F, Kaufmann DE.  2012.  Role of PD-1 in HIV pathogenesis and as target for therapy.. Curr HIV/AIDS Rep. 9(1):81-90.
Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose NA, Hoxie JA, Connors M et al..  2012.  Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.. J Virol. 86(10):5844-56.
Doria-Rose NA, Georgiev I, O'Dell S, Chuang G-Y, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF et al..  2012.  A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.. J Virol. 86(15):8319-23.
Mir KD, Bosinger SE, Gasper M, Ho O, Else JG, Brenchley JM, Kelvin DJ, Silvestri G, Hu S-L, Sodora DL.  2012.  Simian immunodeficiency virus-induced alterations in monocyte production of tumor necrosis factor alpha contribute to reduced immune activation in sooty mangabeys.. J Virol. 86(14):7605-15.
West AP, Diskin R, Nussenzweig MC, Bjorkman PJ.  2012.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.. Proc Natl Acad Sci U S A. 109(30):E2083-90.
Guenaga J, Wyatt RT.  2012.  Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.. PLoS Pathog. 8(7):e1002806.
Sekaly R-P, Pulendran B.  2012.  Systems biology in understanding HIV pathogenesis and guiding vaccine development.. Curr Opin HIV AIDS. 7(1):1-3.
Nakaya HI, Pulendran B.  2012.  Systems vaccinology: its promise and challenge for HIV vaccine development.. Curr Opin HIV AIDS. 7(1):24-31.
Walker BD, McMichael A.  2012.  The T-Cell Response to HIV.. Cold Spring Harb Perspect Med.
Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T, Brumme ZL, Schneidewind A et al..  2012.  TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.. Nat Immunol. 13(7):691-700.
Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun T-W, Churchill M, Di Mascio M, Katlama C et al..  2012.  Towards an HIV cure: a global scientific strategy.. Nat Rev Immunol. 12(8):607-14.
Vanderford TH, Slichter C, Rogers KA, Lawson BO, Obaede R, Else JG, Villinger F, Bosinger SE, Silvestri G.  2012.  Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation.. Blood. 119(24):5750-7.
Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro JM, Sanmiguel A, Seaman MS, Ferrari G et al..  2012.  Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.. Nature. 482(7383):89-93.
Doehle BP, Chang K, Rustagi A, McNevin J, McElrath JM, Gale M.  2012.  Vpu Mediates Depletion of Interferon Regulatory Factor 3 during HIV Infection by a Lysosome-Dependent Mechanism.. J Virol. 86(16):8367-74.
Doehle BP, Chang K, Fleming L, McNevin J, Hladik F, McElrath JM, Gale M.  2012.  Vpu-Deficient HIV Strains Stimulate Innate Immune Signaling Responses in Target Cells.. J Virol. 86(16):8499-506.
Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P, Wang S-K, Ramos A, Chan-Hui P-Y, Moyle M et al..  2011.  Broad neutralization coverage of HIV by multiple highly potent antibodies.. Nature. 477(7365):466-70.
Novitsky V, Ndung'u T, Wang R, Bussmann H, Chonco F, Makhema J, De Gruttola V, Walker BD, Essex M.  2011.  Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection.. AIDS. 25(12):1515-22.
Lingappa JR, Petrovski S, Kahle E, Fellay J, Shianna K, McElrath JM, Thomas KK, Baeten JM, Celum C, Wald A et al..  2011.  Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure.. PLoS One. 6(12):e28632.
Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, Kwong PD, Karlsson Hedestam GB, Wyatt RT.  2011.  Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.. PLoS One. 6(1):e16074.
De Rosa SC, Thomas EP, Bui J, Huang Y, DeCamp AC, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R et al..  2011.  HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.. J Immunol. 187(6):3391-401.
Mörner A, Jansson M, Bunnik EM, Schøller J, Vaughan R, Wang Y, Montefiori DC, Otting N, Bontrop R, Bergmeier LA et al..  2011.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.. J Virol. 85(13):6442-52.
Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, Gnanapragasam PNP, Abadir A, Seaman MS, Nussenzweig MC et al..  2011.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.. Science. 334(6060):1289-93.
Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, Carlson JM, Heckerman D, Wang B, Losina E, Leshwedi M et al..  2011.  Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.. J Virol. 85(8):3996-4006.
Radebe M, Nair K, Chonco F, Bishop K, Wright JK, van der Stok M, Bassett IV, Mncube Z, Altfeld M, Walker BD et al..  2011.  Limited immunogenicity of HIV CD8+ T-cell epitopes in acute Clade C virus infection.. J Infect Dis. 204(5):768-76.
Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE et al..  2011.  Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.. J Virol. 85(17):8954-67.